Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (a...

Full description

Bibliographic Details
Main Authors:	Howell, Anthony, Dowsett, Mitch
Format:	Online
Language:	English
Published:	BioMed Central 2004
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064088/

id	pubmed-1064088
recordtype	oai_dc
spelling	pubmed-10640882005-03-11 Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens Howell, Anthony Dowsett, Mitch Review Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs. BioMed Central 2004 2004-10-06 /pmc/articles/PMC1064088/ /pubmed/15535858 http://dx.doi.org/10.1186/bcr945 Text en Copyright © 2004 BioMed Central Ltd
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Howell, Anthony Dowsett, Mitch
spellingShingle	Howell, Anthony Dowsett, Mitch Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
author_facet	Howell, Anthony Dowsett, Mitch
author_sort	Howell, Anthony
title	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
title_short	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
title_full	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
title_fullStr	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
title_full_unstemmed	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
title_sort	endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens
description	Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs.
publisher	BioMed Central
publishDate	2004
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064088/
_version_	1611372951274258432

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens

Similar Items